GSK4527226

TERMINATED · PHASE2 · Alzheimer's Disease

The study was terminated early due to meeting pre-specified efficacy futility criteria at planned interim analysis.

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.